Recursion Pharmaceuticals Inc Cl A (RXRX) Stock Price, Quote & News

Company Profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-12...

Industry: Biotechnology

Sector: Healthcare

Phone: 385 269 0203

Website: www.recursion.com

Address:

41 South Rio Grande Street, Salt Lake City, United States

Gemology May. 15 at 4:18 PM

$TEM $RXRX $CREG $INFQ guide

0 · Reply

Zio_Fauss May. 15 at 3:21 PM

$RXRX In all these years, I’ve never seen a stock keep dropping like a knife with no brakes, while everyone is still acting healthy and happy, including institutions and funds that keep adding more. Either this is the greatest team sport Wall Street has ever played, or there’s something seriously big going on behind the curtain. Because at this point, this chart isn’t moving like a stock anymore. It’s moving like it knows something we don’t.

0 · Reply

Bazzzigar May. 15 at 1:17 PM

$RXRX join with KR

0 · Reply

Tobitski May. 15 at 12:40 PM

$RXRX 🐳 buying like never before. So am I 😅 Retail always shit there pants when things decline. Well for me that’s a opportunity. And I guess some would agree 😅. Before this year ends tables will have turned 🍻 Good luck all ✌🏻

0 · Reply

Brodman May. 15 at 12:39 PM

$RXRX $2's are here....next stop $1's. Hopefully they can survive, keep in mind they haven't gotten a drug approved in their HISTORY.

0 · Reply

Spartangio May. 15 at 12:25 PM

$RXRX SoftBank still 13,636,515 shares unchanged

0 · Reply

Brodman May. 15 at 11:43 AM

$RXRX Record lows coming, $2's starting today....Nvidia was smart dumping this before it becomes a penny stock.

0 · Reply

Traderjoe2869 May. 15 at 10:43 AM

$RXRX feels like we heading back to the Lows . Or new lows . AI biotech trade doesn’t seem so hot . I feel like since nvidia sold out here it’s been frowned upon .

1 · Reply

Michaela4m May. 15 at 1:30 AM

$RXRX

1 · Reply

theRockSeys May. 14 at 9:43 PM

$RXRX I remeber when I was in early day pltr and intel. Now I’m here.

1 · Reply

Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley

May 12, 2026, 1:00 PM EDT - 2 days ago

Recursion Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 11:49 AM EDT - 3 days ago

These 10 ‘HALO' stocks protect your portfolio from the AI bubble

AWR ES HTO PCG PPL SR SRE

2026-05-07T09:29:09.000Z - 8 days ago

Recursion Pharmaceuticals reports Q1 EPS (22c), consensus (26c)

May 6, 2026, 8:00 AM EDT - 9 days ago

Recursion Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 6:30 AM EDT - 9 days ago

Recursion Reports First Quarter Financial Results and Provides Business Update

Apr 30, 2026, 4:30 PM EDT - 14 days ago

Recursion Announces Board Transition

2026-04-30T15:21:19.000Z - 15 days ago

Recursion Pharmaceuticals price target lowered to $10 from $11 at JPMorgan

Apr 29, 2026, 7:59 AM EDT - 16 days ago

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Apr 13, 2026, 12:45 PM EDT - 4 weeks ago

Recursion Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:00 AM EDT - 5 weeks ago

Recursion to Participate in Upcoming Investor Conferences

Mar 31, 2026, 9:00 AM EDT - 6 weeks ago

Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform

2026-03-25T12:06:43.000Z - 7 weeks ago

Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer

EXEL

Mar 25, 2026, 7:59 AM EDT - 7 weeks ago

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

Mar 17, 2026, 3:45 PM EDT - 2 months ago

Recursion Pharmaceuticals Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 9, 2026, 8:00 AM EDT - 2 months ago

Recursion Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-05T13:44:59.000Z - 2 months ago

PacBio appoints Gibson to Board of Directors

PACB

Mar 2, 2026, 9:50 AM EST - 2 months ago

Recursion Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-26T11:32:07.000Z - 2 months ago

Recursion Pharmaceuticals price target lowered to $6 from $7 at BofA

2026-02-25T14:40:25.000Z - 2 months ago

Unusually active option classes on open February 25th

CRCL FRMI GEO JBS LAC LOW PYPL

Feb 25, 2026, 8:00 AM EST - 2 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q4 2025

2026-02-25T11:47:23.000Z - 2 months ago

Recursion Pharmaceuticals reports Q4 EPS (21c), consensus (32c)

Feb 25, 2026, 6:30 AM EST - 2 months ago

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 8:00 AM EST - 2 months ago

Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

2026-02-19T14:15:00.000Z - 3 months ago

Cathie Wood Loads Up on Biotech Stocks While Trimming Several Tech Positions

CRM CRSP DKNG PD TER TWST

2026-02-19T01:15:11.000Z - 3 months ago

Cathie Wood’s ARK Investment buys 1.2M shares of Recursion Pharmaceuticals today

Feb 18, 2026, 8:30 AM EST - 3 months ago

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Feb 18, 2026, 5:43 AM EST - 3 months ago

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.

APLD NVDA

2026-02-12T13:10:56.000Z - 3 months ago

Recursion Pharmaceuticals reports grant of inducement awards

Jan 16, 2026, 12:45 PM EST - 4 months ago

Recursion Pharmaceuticals Transcript: 28th Annual Needham Growth Conference Virtual

Jan 13, 2026, 1:30 PM EST - 4 months ago

Recursion Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:59 AM EST - 4 months ago

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 11:05 AM EST - 5 months ago

What's Happening With RXRX Stock?

Dec 8, 2025, 8:00 AM EST - 5 months ago

Recursion Pharmaceuticals Transcript: Study Update

Dec 8, 2025, 7:32 AM EST - 5 months ago

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8, 2025, 7:30 AM EST - 5 months ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Dec 1, 2025, 8:30 AM EST - 5 months ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Nov 18, 2025, 5:30 AM EST - 6 months ago

Recursion Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 8:00 AM EST - 6 months ago

Recursion Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 8:00 AM EST - 6 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 5, 2025, 6:30 AM EST - 6 months ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:28 AM EST - 6 months ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Sep 8, 2025, 4:05 PM EDT - 8 months ago

Recursion Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 2:30 PM EDT - 9 months ago

Recursion Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Recursion Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 5, 2025, 6:30 AM EDT - 10 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 29, 2025, 8:00 AM EDT - 10 months ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jun 10, 2025, 3:20 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 10, 2025, 6:14 AM EDT - 1 year ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 6, 2025, 10:00 AM EDT - 1 year ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

May 15, 2025, 10:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: 53rd Annual JPMorgan Global Technology, Media and Communications Conference

May 13, 2025, 1:00 PM EDT - 1 year ago

Recursion Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference

May 5, 2025, 8:00 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q1 2025

May 5, 2025, 6:00 AM EDT - 1 year ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025, 12:45 PM EDT - 1 year ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Apr 28, 2025, 8:27 AM EDT - 1 year ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 22, 2025, 8:34 PM EDT - 1 year ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 16, 2025, 8:30 AM EDT - 1 year ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Recursion to Participate in Upcoming Investor Conference

Feb 28, 2025, 8:30 AM EST - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 28, 2025, 6:30 AM EST - 1 year ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 24, 2025, 8:00 AM EST - 1 year ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 18, 2025, 11:00 AM EST - 1 year ago

Altitude Lab Startups Raise $154M in Capital

Feb 5, 2025, 5:24 PM EST - 1 year ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Jan 13, 2025, 10:30 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 7, 2025, 9:15 AM EST - 1 year ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 6, 2025, 8:30 AM EST - 1 year ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Dec 20, 2024, 4:05 PM EST - 1 year ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 11, 2024, 10:00 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Bank of America Global A.I. Conference 2024

Dec 9, 2024, 7:00 PM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Status Update

Dec 9, 2024, 6:00 PM EST - 1 year ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Nov 20, 2024, 8:00 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 20, 2024, 7:30 AM EST - 1 year ago

Recursion Pharmaceuticals Transcript: Status Update

Nov 20, 2024, 7:00 AM EST - 1 year ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nov 13, 2024, 9:08 AM EST - 1 year ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Nov 12, 2024, 4:54 PM EST - 1 year ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Oct 30, 2024, 8:22 AM EDT - 1 year ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Oct 2, 2024, 8:32 AM EDT - 1 year ago

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Sep 3, 2024, 8:11 AM EDT - 1 year ago

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Aug 9, 2024, 9:00 AM EDT - 1 year ago

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

Aug 8, 2024, 2:41 PM EDT - 1 year ago

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Recursion Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 7:39 AM EDT - 1 year ago

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Gemology May. 15 at 4:18 PM

$TEM $RXRX $CREG $INFQ guide

0 · Reply

Zio_Fauss May. 15 at 3:21 PM

0 · Reply

Bazzzigar May. 15 at 1:17 PM

$RXRX join with KR

0 · Reply

Tobitski May. 15 at 12:40 PM

0 · Reply

Brodman May. 15 at 12:39 PM

$RXRX $2's are here....next stop $1's. Hopefully they can survive, keep in mind they haven't gotten a drug approved in their HISTORY.

0 · Reply

Spartangio May. 15 at 12:25 PM

$RXRX SoftBank still 13,636,515 shares unchanged

0 · Reply

Brodman May. 15 at 11:43 AM

$RXRX Record lows coming, $2's starting today....Nvidia was smart dumping this before it becomes a penny stock.

0 · Reply

Traderjoe2869 May. 15 at 10:43 AM

$RXRX feels like we heading back to the Lows . Or new lows . AI biotech trade doesn’t seem so hot . I feel like since nvidia sold out here it’s been frowned upon .

1 · Reply

Michaela4m May. 15 at 1:30 AM

$RXRX

1 · Reply

theRockSeys May. 14 at 9:43 PM

$RXRX I remeber when I was in early day pltr and intel. Now I’m here.

1 · Reply

Bazzzigar May. 14 at 9:28 PM

$RXRX more drop ahead

0 · Reply

Brodman May. 14 at 8:19 PM

$RXRX Nvidia the world's most valuable company doesn't make many mistakes and they dumped all Recursion stock for a reason and that reason was simple...they aren't going to be successful, get out now rather than later and that's what they did.

0 · Reply

Zio_Fauss May. 14 at 7:10 PM

$RXRX I like money too 🤣 +15% every month sounds great, but trying to catch a falling knife here is killing my brain… 😬🔪 Elkhan is a friend of mine, and I’ll call Lapo to ask John if he has any good news or guidance. 👀

1 · Reply

Spartangio May. 14 at 6:37 PM

$RXRX Exor - Agnelli’s family - they like money 6 mln shares +20%

0 · Reply

Spartangio May. 14 at 4:25 PM

$RXRX That daily action

2 · Reply

Floridaorange May. 14 at 3:42 PM

$RXRX https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/05/52379571/recursion-eyes-breakthrough-with-rec-4881-drug-for-rare-genetic-condition-but-shares-pull-back?utm_source=TechInvestorNews&utm_campaign=partner_feed&utm_medium=referral Needham maintained a Buy and an $8 target. RXRX is moving toward a registrational path for REC-4881 in FAP (Familial Adenomatous Polyposis), which is a serious inherited cancer syndrome. This is not just: “drug enters trial.” Recursion is attempting to use its computational stack to influence regulatory strategy itself. That’s HUGE

2 · Reply

Spartangio May. 14 at 3:24 PM

$RXRX Morgan Stanley raising it 5.5 from 5 Well not bad considering the stock price and recent action

0 · Reply

Trexxxxxxxx May. 14 at 3:18 PM

$RXRX odd that morgan stanley raised PT from 5 to 5.50 considering how this has been trading lately. Pretty minor and i usually dgaf about analyst pt but ill take it 🤷‍♂️

0 · Reply

wyattdog2 May. 14 at 3:16 PM

$RXRX Morgan Stanley Raises Price Target on Recursion Pharmaceuticals to $5.50 From $5, Keeps Equalweight Rating

1 · Reply

Floridaorange May. 14 at 3:05 PM

$RXRX 🎯🐂 https://www.prnewswire.com/news-releases/solid-tumor-treatment-race-heats-up-as-multi-billion-dollar-oncology-market-enters-high-growth-phase-302771552.html

0 · Reply

Lh2838 May. 14 at 2:30 PM

$RXRX Battle going on Institutions hold roughly 323–326M shares Shorts are about 174M shares Float dynamics are getting tighter than many realize because a large portion of shares are locked by institutions and long-term holders. Shares short: ~174.4M Short % of float: ~36% Days to cover: ~17 days Outstanding shares: ~527M

0 · Reply

Brodman May. 14 at 1:47 PM

$RXRX Too many insiders selling and 6 months of declines suggests that this will be a penny stock soon. 12 years and nothing to show for it. Starting to look more and more like they won't be a real player. Dead money!!

0 · Reply

Market Cap	1.62B
Revenue (ttm)	74.68M
Net Income (ttm)	-644.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-863.36%
Debt to Equity Ratio	0.01

Volume	14,999,200
Avg Vol	12,715,282
Day's Range	N/A - N/A
Shares Out	529.91M
Stochastic %K	2%
Beta	1.05
Analysts	Sell
Price Target	$6.57